**Supplementary references**

e1. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004;63:822-827.

e2. Ding Y, Lin H, Liu X, et al. Higher Prevalence of Frailty Among a Sample of HIV-Infected Middle-aged and Older Chinese Adults Is Associated With Neurocognitive Impairment and Depressive Symptoms. The Journal of infectious diseases 2017;215:687-692.

e3. Peluso R, Haase A, Stowring L, Edwards M, Ventura P. A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology 1985;147:231-236.

e4. Budka H. Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). Acta neuropathologica 1986;69:253-258.

e5. Budka H, Wiley CA, Kleihues P, et al. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain pathology (Zurich, Switzerland) 1991;1:143-152.

e6. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV medicine 2013;14:136-144.

e7. Foca E, Magro P, Motta D, et al. Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. International journal of molecular sciences 2016;17:434.

e8. Campbell JH, Ratai EM, Autissier P, et al. Anti-alpha4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. PLoS pathogens 2014;10:e1004533.

e9. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57-69.

e10. Gill AJ, Kovacsics CE, Vance PJ, Collman RG, Kolson DL. Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy. Journal of virology 2015;89:10656-10667.

e11. Ru W, Tang SJ. HIV-1 gp120Bal down-Regulates Phosphorylated NMDA Receptor Subunit 1 in Cortical Neurons via Activation of Glutamate and Chemokine Receptors. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2016;11:182-191.

e12. Wachter C, Eiden LE, Naumann N, Depboylu C, Weihe E. Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy. Journal of neuroinflammation 2016;13:272.

e13. Chen NC, Partridge AT, Tuzer F, et al. Induction of a Senescence-Like Phenotype in Cultured Human Fetal Microglia During HIV-1 Infection. The journals of gerontology Series A, Biological sciences and medical sciences 2018.

e14. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. Journal of acquired immune deficiency syndromes (1999) 2012;60:234-243.

e15. Gill AJ, Kovacsics CE, Cross SA, et al. Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. The Journal of clinical investigation 2014;124:4459-4472.

e16. Ambegaokar SS, Kolson DL. Heme oxygenase-1 dysregulation in the brain: implications for HIV-associated neurocognitive disorders. Current HIV research 2014;12:174-188.

e17. Quasney MW, Zhang Q, Sargent S, Mynatt M, Glass J, McArthur J. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 2001;50:157-162.

e18. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proceedings of the National Academy of Sciences of the United States of America 2002;99:13795-13800.

e19. van Rij RP, Portegies P, Hallaby T, et al. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. The Journal of infectious diseases 1999;180:854-857.

e20. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. Journal of neuroimmunology 1999;93:172-181.

e21. Sorensen TL, Trebst C, Kivisakk P, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. Journal of neuroimmunology 2002;127:59-68.

e22. Sui Y, Stehno-Bittel L, Li S, et al. CXCL10-induced cell death in neurons: role of calcium dysregulation. The European journal of neuroscience 2006;23:957-964.

e23. Slimani H, Charnaux N, Mbemba E, et al. Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochimica et biophysica acta 2003;1617:80-88.

e24. Lassmann H. Multiple Sclerosis Pathology. Cold Spring Harbor perspectives in medicine 2018;8.

e25. Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 2015;16:584-589.

e26. Rozzi SJ, Avdoshina V, Fields JA, Mocchetti I. Human immunodeficiency virus Tat impairs mitochondrial fission in neurons. Cell death discovery 2018;4:8.

e27. Gurwitz KT, Burman RJ, Murugan BD, et al. Time-Dependent, HIV-Tat-Induced Perturbation of Human Neurons In Vitro: Towards a Model for the Molecular Pathology of HIV-Associated Neurocognitive Disorders. Frontiers in molecular neuroscience 2017;10:163.

e28. Marks WD, Paris JJ, Schier CJ, et al. HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. Journal of neurovirology 2016;22:747-762.

e29. Gaskill PJ, Miller DR, Gamble-George J, Yano H, Khoshbouei H. HIV, Tat and dopamine transmission. Neurobiology of disease 2017;105:51-73.

e30. Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, Bruce-Keller AJ. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxidants & redox signaling 2009;11:193-204.

e31. Jadhav VS, Krause KH, Singh SK. HIV-1 Tat C modulates NOX2 and NOX4 expressions through miR-17 in a human microglial cell line. Journal of neurochemistry 2014;131:803-815.

e32. van Marle G, Henry S, Todoruk T, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004;329:302-318.

e33. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topics in antiviral medicine 2011;19:137-142.

e34. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. European journal of neurology 2006;13:604-610.

e35. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.

e36. Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejfar A, Wiendl H, Klotz L. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e183.

e37. Li R, Rezk A, Ghadiri M, et al. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. Journal of immunology (Baltimore, Md : 1950) 2017;198:691-698.

e38. Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta neuropathologica 2015;130:279-295.

e39. Altmeyer P, Hartwig R, Matthes U. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 1996;47:190-196.

e40. Ghadiri M, Rezk A, Li R, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm 2017;4:e340.

e41. Diebold M, Sievers C, Bantug G, et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. Journal of autoimmunity 2018;86:39-50.

e42. Williams SA, Chen LF, Kwon H, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. The Journal of biological chemistry 2004;279:42008-42017.

e43. Orecchini E, Doria M, Michienzi A, et al. The HIV-1 Tat protein modulates CD4 expression in human T cells through the induction of miR-222. RNA biology 2014;11:334-338.

e44. Scarpellini B, Zanoni M, Sucupira MC, et al. Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. PloS one 2016;11:e0161920.

e45. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical neuropharmacology 2010;33:91-101.

e46. Castellano P, Prevedel L, Eugenin EA. HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim. Scientific reports 2017;7:12866.

e47. Asghar MY, Kemppainen K, Lassila T, Tornquist K. Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2. PloS one 2018;13:e0196992.

e48. Geffin R, Martinez R, de Las Pozas A, Issac B, McCarthy M. Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV. Journal of neurovirology 2017;23:808-824.

e49. Ohtani R, Mori M, Uchida T, et al. Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Multiple sclerosis journal - experimental, translational and clinical 2018;4:2055217318759692.

e50. Li L, Liu J, Delohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. Journal of neuroimmunology 2013;265:82-90.

e51. Huang JL, Wu SY, Xie XJ, Wang MX, Zhu S, Gu JR. Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. European journal of pharmacology 2011;670:304-310.

e52. von Bismarck O, Dankowski T, Ambrosius B, et al. Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e446.

e53. Metz LM, Li DKB, Traboulsee AL, et al. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med 2017;376:2122-2133.

e54. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. Journal of leukocyte biology 2005;78:135-143.

e55. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-751.

e56. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308.

e57. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014;59:1787-1797.

e58. Fogel GB, Lamers SL, Levine AJ, et al. Factors related to HIV-associated neurocognitive impairment differ with age. Journal of neurovirology 2015;21:56-65.

e59. Mukerji SS, Locascio JJ, Misra V, et al. Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV-Infected Men on Antiretroviral Therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016;63:1130-1139.

e60. Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS (London, England) 2016;30:65-73.

e61. Patel PB, Spudich SS. Global Health Neurology: HIV/AIDS. Seminars in neurology 2018;38:238-246.